Post by Pierre Fabre Oncology

🚀 When AI becomes a strategic driver for pharmaceutical R&D At Laboratoires Pierre Fabre, artificial intelligence is a strategy designed from the inside, driven by the teams. This is exactly what Audrey Kauffmann, Head of Data Science, AI and Biometry, highlights in her interview with IT for Business (May 2026). Audrey explains how their AI strategy: • was born within a dedicated data science and biometry team, working closely with scientists, clinicians and development experts • relies on an intimate understanding of drug discovery and development, as well as the associated data • remains fully aligned with R&D priorities and operational needs 💡 Above all, Audrey insists on a strong strategic choice : “We chose to keep control over our AI strategy.” In a field as specific and demanding as pharmaceutical R&D, maintaining scientific, regulatory and operational ownership while leveraging AI becomes a true advantage. For Audrey, AI does not replace researchers. It: • accelerates and guides research • frees up time at the bench • reinforce the role of human judgment, creativity and experimental validation. This vision of AI is pragmatic, responsible and firmly rooted in real-world practice. A truly inspiring example of what AI transformation can look like in the pharmaceutical industry. 👉 This is just the beginning of our AI journey in R&D at Laboratoires Pierre Fabre. More to come. #AI #RD #Pharma #DataScience #Biometry #Innovation #PierreFabre 💊